|  |
| --- |
| September 26, 2016 |
|  |
| Contact person Dr. Jürgen Krauter  Head of Communications  Nutrition & Care  Phone +49 6181 59-6847  Fax +49 6181 59-76847  juergen.krauter@evonik.com |
| Contact person specialized press Hannah Rausche  Head of Communications  Health Care  Phone +49 6151 18-3567  Fax +49 6181 59-76847  hannah.rausche@evonik.com |
| Evonik Nutrition & Care GmbH  Rellinghauser Straße 1-11  45128 Essen  Phone +49 201 177-01  Fax +49 201 177-3475 Germany  www.evonik.com  **Supervisory Board**  Dr. Ralph Sven Kaufmann, Chairman  Management Board  Dr. Reiner Beste, Chairman  Dr. Hans Josef Ritzert Michael Gattermann Markus Schäfer  Registered office Essen  Registered court  Essen local court  Commercial registry B 25784 |

**Evonik strengthens its position as a leading service provider for parenteral drug delivery technologies**

* Integration of Canadian biotechnology company Transferra Nanosciences Inc. has begun
* Expanded technology portfolio for pharmaceutical customers includes liposomal drug delivery systems
* Services range from prototype identification to commercial manufacturing of parenteral drugs

Essen, Germany. The end of August marked the completion of the acquisition of biotechnology company Transferra Nanosciences Inc., formerly known as Northern Lipids Inc., further strengthening Evonik’s Health Care Business Line’s position as a leading provider of services for the development of drug delivery systems. The integration process for the contract development and manufacturing organization, based in Burnaby, Canada has recently begun. Transferra is now affiliated to Evonik Canada Inc., and operates under the name of Evonik Transferra Nanosciences.

Transferra has unique expertise in liposomal drug delivery systems and offers a broad variety of products and services for the development of parenteral drugs. Its acquisition extends and enhances Evonik’s parenteral formulations portfolio.

Evonik Health Care ranks among the leading providers of technologies, services for formulation development and GMP manufacturing, and pharmaceutical polymers (EUDRAGIT® and RESOMER®) for controlled release drug delivery systems.

Dr. Jean-Luc Herbeaux, Executive Vice President and Head of Evonik’s Health Care Business Line, explains: “By inviting Transferra, a leading player in liposomal drug delivery, to join our team, we broaden Evonik’s offering for the pharmaceutical industry. We can now service customers in the key complex injectable drug formulation technologies based on polymers and liposomal nanoparticles. This positions Evonik as a partner of choice for the development and manufacturing of a broad range of injectable drug products based, for example, on nucleotides or cytostatic compounds.”

Evonik Transferra Nanosciences’ products and services will be highlighted at this year’s CPhI trade show in Barcelona, at the Evonik booth (C50) in hall 2.

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

**About Nutrition & Care**

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around   
€4.9 billion in 2015.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.